Figures computed from official regulatory filings — .
Analysttarget 51.67 USD (+99%) · consensus 5/5 · 2 buy · 0 hold · 0 sell
Ownershipinsiders 28.29% · institutions 153.02% · short 84.6% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Faeth Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
178 buys51 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Vousden Karen H | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Craver Josiah | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Parikh Anand Kiran | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $43.8K | conv 47Cluster | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $19.4K | conv 48Cluster | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $14.5K | conv 47Cluster | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $39.1K | conv 47Cluster | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $103K | conv 58Cluster | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $106.3K | conv 49Cluster | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $34.7K | conv 48Cluster | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $77.9K | conv 50Cluster | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $104.9K | conv 51Cluster | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $2.6K | conv 47Cluster | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $91.7K | conv 50Cluster | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $13.7K | conv 48Cluster | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $72.9K | conv 50Cluster | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $2.8K | conv 46Cluster | SEC |
| Parikh Anand Kiran | Exercise | $9.5K | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $23.3K | conv 88ClusterFirst in 12mo | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $77.5K | conv 91ClusterFirst in 12mo | SEC |
| Parikh Anand Kiran | Buy | $55.4K | conv 63ClusterFirst in 12mo | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $11K | conv 47Cluster | SEC |
| Parikh Anand Kiran | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Parikh Anand Kiran | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| STEPHENSON BRIAN Ctrack record | Buy | $35.5K | conv 87ClusterFirst in 12mo | SEC |